SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fjällskog Marie Louise) "

Sökning: WFRF:(Fjällskog Marie Louise)

  • Resultat 1-10 av 71
  • [1]234567...8Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Aaltonen, Kirsimari, et al. (författare)
  • Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides
  • 2006
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 94:11, s. 1697-1702
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Cyclin A has in some studies been associated with poor breast cancer survival, although all studies have not confirmed this. Its prognostic significance in breast cancer needs evaluation in larger studies. Tissue microarray (TMA) technique allows a simultaneous analysis of large amount of tumours on a single microscopic slide. This makes a rapid screening of molecular markers in large amount of tumours possible. Because only a small tissue sample of each tumour is punched on an array, the question has arisen about the representativeness of TMA when studying markers that are expressed in only a small proportion of cells. For this reason, we wanted to compare cyclin A expression on TMA and on traditional large sections. Two breast cancer TMAs were constructed of 200 breast tumours diagnosed between 1997-1998. TMA slides and traditional large section slides of these 200 tumours were stained with cyclin A antibody and analysed by two independent readers. The reproducibility of the two readers' results was good or even very good, with kappa values 0.71-0.87. The agreement of TMA and large section results was good with kappa value 0.62-0.75. Cyclin A overexpression was significantly (P&lt;0.001) associated with oestrogen receptor and progesterone receptor negativity and high grade both on TMA and large sections. Cyclin A overexpression was significantly associated with poor metastasis-free survival both on TMA and large sections. The relative risks for metastasis were similar on TMA and large sections. This study suggests that TMA technique could be useful to study histological correlations and prognostic significance of cyclin A on breast cancer on a large scale.</p>
  •  
2.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.
  • 2009
  • Ingår i: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - American Association for Cancer Research. - 1538-7755. ; 18, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6).
  •  
3.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
  • 2009
  • Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - 1055-9965 .- 1538-7755. ; 18:9, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Proliferative markers are not recommended as prognostic   factors for clinical use in breast cancer due to lack of   standardization in methodology. However, proliferation is driving   several gene expression signatures emphasizing the need for a reliable   proliferative marker IF or clinical use. Studies suggest that cyclin A   is a prognostic marker with satisfying reproducibility. We investigated   cyclin A as a prognostic marker in node-negative breast cancer using   previously defined cutoff values.   Patients and Methods: In a case-control study, we defined 190 women who   died from breast cancer as cases and 190 women alive at the time for   the corresponding case's death as controls. Inclusion criteria were   tumor size &lt;= 50 mm, no lymph node metastases and no adjuvant   chemotherapy. Tumor tissues were immunostained for cyclin A using   commercially available antibodies.   Results: We found a statistically significant association between   expression of cyclin A and breast cancer death in a univariate model:   odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI),   1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio   for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI,   1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly   correlated to Ki67 and grade why a model including all was not   appropriate.   Conclusions: Cyclin A is a prognostic factor for breast cancer death in   node-negative patients using standardized methodology regarding scoring   and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of  low and high risk breast cancer.</p>
  •  
4.
  • Ahlin, Cecilia, et al. (författare)
  • Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
  • 2009
  • Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - 1055-9965 .- 1538-7755. ; 18:9, s. 2501-2506
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker IF or clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and Methods: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size &lt;= 50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. Results: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. Conclusions: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6)</p>
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Ahlin, Cecilia, et al. (författare)
  • Ki67 and cyclin A as prognostic factors in early breast cancer : What are the optimal cut-off values?
  • 2007
  • Ingår i: Histopathology. - 0309-0167 .- 1365-2559. ; 51:4, s. 491-498
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>AIMS: To find the optimal cut-off values for cyclin A and Ki67 in early breast cancer tumours and to evaluate their prognostic values. METHODS AND RESULTS: Tissue microarray (TMA) slides were constructed from 570 T1-4 N0-1 M0 breast cancer tumours. The TMA slides were stained for cyclin A and Ki67 using immunohistochemistry with commercial antibodies. To investigate the optimal cut-off values for cyclin A, Ki67 average and maximum values the material was split into two parts at cut-offs defined by dividing it into deciles. For each cut-off value the relative risk (RR) for metastasis-free survival (MFS) and overall survival (OS) was calculated comparing patients with high versus low cyclin A or Ki67 expression. When using a cut-off value around the seventh decile, cyclin A and Ki67 score correlated with the highest RR ratio for MFS in the chemotherapy-naïve subgroup. Among patients having received adjuvant chemotherapy, no statistically significant differences in MFS or OS were found. CONCLUSIONS: The optimal cut-off value for cyclin A average is 8% and for cyclin A maximum value 11%; for Ki67 the corresponding values are 15% and 22%. Additional studies are needed to verify these results.</p>
  •  
9.
  • Ahnström Waltersson, Marie, 1976- (författare)
  • Cell cycle alterations and 11q13 amplification in breast cancer prediction of adjuvant treatment response
  • 2009
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • <p>The growth and development of the breast is to a large extent regulated by oestrogens through the oestrogen receptor (ER). Activation of the ERα triggers transcription of genes that are important for cell proliferation and stimulates entry into the G1 phase of the cell cycle. In breast cancer the ERα is often upregulated and is therefore a suitable target for adjuvant therapies such as tamoxifen. Although tamoxifen is an effective treatment in most cases, tumours sometimes acquire resistance to the drug. The aim of this thesis was to investigate the impact of G1 phase proteins and 11q13 amplification on prognosis and treatment response in breast cancer. The material used was from a clinical trial in which postmenopausal breast cancer patients were randomised to chemotherapy or radiotherapy and tamoxifen or no adjuvant treatment. We studied the expression of cyclin D1, cyclin E and Rb with immunohisochemistry and amplification of <em>CCND1</em> and PAK1 with real time PCR. We found that among patients with high tumour expression of cyclin D1, overexpression of ErbB2 was associated with reduced recurrence-free survival. Both cyclin D1 and cyclin E overexpression were associated with reduced tamoxifen response. High expression of cyclin D1 has been found to induce ligand independent activation of ER<em>α</em> in breast cancer cells and might also switch tamoxifen from acting as an antagonist to an agonist. Overexpression of cyclin E has been shown to be associated with expression of low molecular weight isoforms of the protein that possess an increased kinase activity and are insensitive to p21 and p27 inhibition. Furthermore, amplification of 11q13, and in particular the gene PAK1, was a strong predictor of tamoxifen resistance. The pak1 protein is involved in phosphorylation and ligand independent activation of the ER<em>α</em>. We also found that lost expression of either p53 or Rb reduced the patients benefit from radiotherapy compared with patients with normal expression of both proteins. Normally, ionizing radiation upregulates p53 resulting in G1 arrest or apoptosis. If either functional p53 or Rb is missing the cells can proceed from G1 to the S phase despite damaged DNA. The expression of the microRNA, miR-206, was analysed with real time PCR, and the results showed that high expression of miR-206 correlated to low expression of ERα and 11q13 amplification. In vitro studies have shown that miR-206 negatively regulates the expression of ERα. Taken together the G1 regulators and amplification of 11q13 seem to have an important role in predicting the patient’s response to adjuvant therapy.</p>
  •  
10.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 71
  • [1]234567...8Nästa
Åtkomst
fritt online (22)
Typ av publikation
tidskriftsartikel (59)
doktorsavhandling (7)
annan publikation (3)
konferensbidrag (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (59)
övrigt vetenskapligt (15)
populärvet., debatt m.m. (2)
Författare/redaktör
Fjällskog, Marie Lou ... (65)
Blomqvist, Carl (22)
Ahlin, Cecilia, (21)
Amini, Rose-Marie (17)
Nilsson, Cecilia, (16)
Hedenfalk, Ingrid, (15)
visa fler...
Jirström, Karin, (12)
Holmberg, Lars, (11)
Holmqvist, Marit (11)
Zhou, Wenjing (9)
Wärnberg, Fredrik, (8)
Eriksson, Barbro, (8)
Fernö, Mårten, (7)
Malmström, Per, (6)
Bendahl, Pär Ola, (6)
Nordin, Karin, (6)
Arving, Cecilia, (6)
Öberg, Kjell, (5)
Tiensuu Janson, Eva, (5)
Grabau, Dorthe, (5)
Ringnér, Markus, (4)
Nilsson-Ihrfelt, Eli ... (4)
Bergkvist, Leif, (4)
Olsson, Hans (3)
Nevanlinna, Heli (3)
Rydén, Lisa, (3)
Stål, Olle, (3)
Borgquist, Signe, (3)
Fjällskog, Marie-Lou ... (3)
Grönberg, Malin, (3)
Thorstenson, Sten, (3)
Lauss, Martin, (3)
Aaltonen, Kirsimari (2)
Ferno, Marten, (2)
Ahlin, C (2)
Peterson, Magnus, 19 ... (2)
Ringberg, Anita (2)
Abdsaleh, Shahin, (2)
Johansson, Christine ... (2)
Ahlgren, Johan, (2)
Blomqvist, Carl Prof ... (2)
Lundgren, Claudia, 1 ... (2)
Tolockiene, Egle, (2)
Bergh, Jonas (2)
Andersson, Gerhard (2)
Andersson, Gerhard, ... (2)
Grönberg, Malin, 198 ... (2)
Welin, Staffan, (2)
Granberg, Dan, (2)
Hedenfalk, Ingrid A. ... (2)
visa färre...
Lärosäte
Uppsala universitet (55)
Lunds universitet (8)
Linköpings universitet (4)
Örebro universitet (2)
Umeå universitet (1)
Mälardalens högskola (1)
visa fler...
Karolinska Institutet (1)
visa färre...
Språk
Engelska (65)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (65)
Samhällsvetenskap (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy